Alnylam Pharmaceuticals (ALNY) EBIAT: 2009-2025
Historic EBIAT for Alnylam Pharmaceuticals (ALNY) over the last 16 years, with Sep 2025 value amounting to $251.1 million.
- Alnylam Pharmaceuticals' EBIAT rose 325.05% to $251.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.6 million, marking a year-over-year increase of 113.11%. This contributed to the annual value of -$278.2 million for FY2024, which is 36.82% up from last year.
- According to the latest figures from Q3 2025, Alnylam Pharmaceuticals' EBIAT is $251.1 million, which was up 478.84% from -$66.3 million recorded in Q2 2025.
- Over the past 5 years, Alnylam Pharmaceuticals' EBIAT peaked at $251.1 million during Q3 2025, and registered a low of -$405.9 million during Q3 2022.
- Over the past 3 years, Alnylam Pharmaceuticals' median EBIAT value was -$66.3 million (recorded in 2025), while the average stood at -$53.7 million.
- Within the past 5 years, the most significant YoY rise in Alnylam Pharmaceuticals' EBIAT was 325.05% (2025), while the steepest drop was 292.43% (2025).
- Quarterly analysis of 5 years shows Alnylam Pharmaceuticals' EBIAT stood at -$258.5 million in 2021, then increased by 19.72% to -$207.5 million in 2022, then surged by 33.55% to -$137.9 million in 2023, then skyrocketed by 39.24% to -$83.8 million in 2024, then skyrocketed by 325.05% to $251.1 million in 2025.
- Its last three reported values are $251.1 million in Q3 2025, -$66.3 million for Q2 2025, and -$57.5 million during Q1 2025.